Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 1 of 5 (20%) have an AI response strategy ready
Seqirus Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 distinct examiners across 3 distinct art units, showing a distributed docket that requires both matter-level and art-unit coordination.
MOU, LIYUAN is the busiest examiner, with 1 pending matter. No single examiner accounts for more than that portion of the current workload, so counsel should organize responses by examiner and art-unit context.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| YU, HONG | 1 | 31.1% | +5.7% |
| BASQUILL, SEAN M | 1 | 38.8% | +21.7% |
| CHEN, STACY BROWN | 1 | 66.1% | +40.4% |
| CORNELIUS, CLAIRE ADRIENNE | 1 | 71.4% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037226 | MULTICISTRONIC RNA VACCINES AND USES THEREOF | CORNELIUS, CLAIRE ADRIENNE | 27d |
| 18702909 | IONIZABLE CATIONIC COMPOUND | MOU, LIYUAN | — |
| 18699125 | LIPID NANOPARTICLE COMPRISING A NUCLEIC ACID-BINDING PROTEIN | YU, HONG | — |
| 18255610 | SELF-REPLICATING RNA AND USES THEREOF | CHEN, STACY BROWN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18702909 | IONIZABLE CATIONIC COMPOUND | MOU, LIYUAN | — |
| 18695917 | IONIZABLE CATIONIC COMPOUNDS FOR MESSENGER RNA DELIVERY | BASQUILL, SEAN M | — |
| 18255610 | SELF-REPLICATING RNA AND USES THEREOF | CHEN, STACY BROWN | — |
| Art Unit | Apps |
|---|---|
| 1614 | 2 |
| 1672 | 2 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18702909 | IONIZABLE CATIONIC COMPOUND | MOU, LIYUAN | 1645 | §102§103§112Other | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18699125 | LIPID NANOPARTICLE COMPRISING A NUCLEIC ACID-BINDING PROTEIN | YU, HONG | 1614 | §102§103 | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18695917 | IONIZABLE CATIONIC COMPOUNDS FOR MESSENGER RNA DELIVERY | BASQUILL, SEAN M | 1614 | §103DP | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18255610 | SELF-REPLICATING RNA AND USES THEREOF | CHEN, STACY BROWN | 1672 | §102§103 | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18037226 | MULTICISTRONIC RNA VACCINES AND USES THEREOF | CORNELIUS, CLAIRE ADRIENNE | 1672 | §103§112 | Final Rejection | 27d | AI Ready | May 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSeqirus Inc. has 5 pending office actions as of October 2026, spread across 3 art units and 5 examiners.
Liyuan Mou has the most, with 1 of Seqirus Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
